SCHEMBL4522964

SCHEMBL4522964

Cc1cccc(N2CCN(CCCCNC(=O)c3cc4ccccc4o3)CC2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 14/20 1.00
HTR1A P08908 12/20 1.00
HTR2A P28223 12/20 1.00
HTR2C P28335 9/20 1.00
DRD2 P14416 9/20 0.73
KCNH2 Q12809 1/20 0.73
DRD4 P21917 5/20 0.66
DRD1 P21728 2/20 0.66
HTR2B P41595 2/20 0.66
ADRA1D P25100 1/20 0.66
ADRA1A P35348 1/20 0.66
ADRA1B P35368 1/20 0.66
MMP13 P45452 1/20 0.66
HRH3 Q9Y5N1 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4522956 0.84 DRD3 (1.00) DRD3HTR1AHTR2AHTR2CDRD2
SCHEMBL13711946 0.83 DRD3 (1.00) DRD3HTR1AHTR2AHTR2CDRD2
SCHEMBL4530290 0.83 DRD3 (1.00) DRD3HTR1AHTR2AHTR2CDRD2
SCHEMBL4522254 0.82 DRD3 (1.00) DRD3HTR1AHTR2AHTR2CDRD2
SCHEMBL15502198 0.81 MMP13 (0.81) DRD3HTR1AHTR2AHTR2CDRD2
SCHEMBL4522662 0.81 DRD3 (1.00) DRD3HTR1AHTR2AHTR2CDRD2
SCHEMBL4536211 0.80 DRD3 (1.00) DRD3HTR1AHTR2AHTR2CDRD2
SCHEMBL4514321 0.80 DRD3 (1.00) DRD3HTR1AHTR2AHTR2CDRD2
SCHEMBL29677250 0.80 MMP13 (1.00) DRD3HTR1AHTR2AHTR2CDRD2
SCHEMBL8343274 0.80 MMP13 (1.00) DRD3HTR1AHTR2AHTR2CDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090238761-A1 Novel Aryl Piperazine Derivatives With Medical Utility UNIVERSITA DEGLI STUDI DI SIENA (IT) 2009-09-24 US claimed
EP-1836192-A2 ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS Universita' Degli Studi di Siena (IT) 2007-09-26 EP claimed
WO-2006072608-A2 ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS UNIVERSITÁ DEGLI STUDI DI SIENA (IT) 2006-07-13 WO claimed
US-20090238761-A1 Novel Aryl Piperazine Derivatives With Medical Utility UNIVERSITA DEGLI STUDI DI SIENA (IT) 2009-09-24 US disclosed
US-20090238761-A1 Novel Aryl Piperazine Derivatives With Medical Utility UNIVERSITA DEGLI STUDI DI SIENA (IT) 2009-09-24 US disclosed
CN-101137645-A Arylpiperazine derivatives for the treatment of neuropsychiatric disorders UNIV SIENA (IT) 2008-03-05 CN disclosed
EP-1836192-A2 ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS Universita' Degli Studi di Siena (IT) 2007-09-26 EP disclosed
WO-2006072608-A2 ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS UNIVERSITÁ DEGLI STUDI DI SIENA (IT) 2006-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090238761-A1 Novel Aryl Piperazine Derivatives With Medical Utility HTR2C, HTR2A, DRD2 DRD3 10/4885HTR1A 15/4885HTR2A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.